Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report)'s share price shot up 0.8% during trading on Tuesday . The stock traded as high as $20.50 and last traded at $19.74. 558,870 shares traded hands during trading, a decline of 48% from the average session volume of 1,084,159 shares. The stock had previously closed at $19.58.
Wall Street Analyst Weigh In
Several research firms recently commented on CAPR. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, October 9th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $8.00 price objective on shares of Capricor Therapeutics in a research note on Friday, September 20th. Oppenheimer reissued an "outperform" rating and set a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Finally, Maxim Group lifted their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a research note on Wednesday, September 25th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $22.60.
Check Out Our Latest Report on CAPR
Capricor Therapeutics Stock Performance
The stock has a market cap of $690.75 million, a PE ratio of -24.83 and a beta of 4.01. The stock has a fifty day moving average price of $7.76 and a 200 day moving average price of $6.16.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. The business had revenue of $3.97 million for the quarter, compared to analysts' expectations of $4.51 million. As a group, equities analysts anticipate that Capricor Therapeutics Inc will post -1.13 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the stock in a transaction on Friday, September 20th. The stock was acquired at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the acquisition, the insider now owns 7,090,351 shares of the company's stock, valued at $38,004,281.36. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 12.00% of the company's stock.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets bought a new position in shares of Capricor Therapeutics in the 1st quarter worth $40,000. Main Street Financial Solutions LLC increased its position in Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company's stock valued at $131,000 after buying an additional 7,500 shares in the last quarter. SG Americas Securities LLC acquired a new position in Capricor Therapeutics during the 3rd quarter valued at about $133,000. Rhumbline Advisers acquired a new position in Capricor Therapeutics during the 2nd quarter valued at about $147,000. Finally, Bank of New York Mellon Corp increased its position in Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company's stock valued at $381,000 after buying an additional 9,040 shares in the last quarter. 21.68% of the stock is owned by institutional investors.
Capricor Therapeutics Company Profile
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Further Reading
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
